CD274 and neoplasm: Immunotherapies that target immune checkpoints (such as PDL1/PD1) aimed at reverting tumor-related immunosuppression are emerging as a standard of care for advanced NSCLC and other cancer types (Egen et al., 2020; Grosser et al., 2019; Sharma and Allison, 2015).